Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00100386 · ClinicalTrials.gov registry record · NA
Strategies to Reduce Transmission of Antimicrobial Resistant Bacteria in Intensive Care Units (STAR*ICU) Trial
A NA study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- NA
- Development phase
- 30,000
- Enrollment target
NCT00100386: Completed NA study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00100386 is a NA study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 30,000 participants, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (2038% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00100386, a NA study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- NA
- Development phase
- 30,000 participants
- Enrollment target
Study Summary
Primary Outcome Measures:Incidence density of colonization with MRSA or VRE (number of new colonization events per 1000 patient days at risk) during the intervention phase. Secondary Outcome Measures:The effect of the 2 strategies on the incidence density of colonization with MRSA and VRE individually will be determined and compared descriptively. The effect of the strategies on the cumulative incidence of bacteremia caused by MRSA and VRE will be determined to assess the clinical relevance of the strategy in preventing infection. The trial will evaluate the frequency of hand hygiene and the use of gloves and gowns by healthcare workers to substantiate whether the effect of the intensive control strategy is mediated, as expected, by an increase in the use of gloves and gowns due to an increase in the number of patients cared for using Contact Precautions.
Interventions
- PROCEDURE Intensive Control Strategy
- BEHAVIORAL Standard Control Strategy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30,000 participants |
| Start Date | 2005-03 |
| Est. Completion | 2006-08 |
| Phase | NA |
What the finished NCT00100386 record still lists
NCT00100386 is an interventional study that assigns participants to a tested intervention. Its 30,000 participants enrollment target places it among the larger protocols in the corpus, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (2038% higher).
The record links to 0 conditions, and to 2 interventions - of which Intensive Control Strategy is the first listed.
NCT00100386 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00100386 about?
NCT00100386 is a clinical study titled "Strategies to Reduce Transmission of Antimicrobial Resistant Bacteria in Intensive Care Units (STAR*ICU) Trial". Primary Outcome Measures:Incidence density of colonization with MRSA or VRE (number of new colonization events per 1000 patient days at risk) during the intervention phase. Secondary Outcome Measures:The effect of the 2 strategies on the incidence density of colonization with MRSA and VRE individual...
What is the current status of trial NCT00100386?
This trial is currently completed. It is a NA study. The enrollment target is 30,000 participants. The study started on 2005-03. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00100386?
The interventions under investigation include: Intensive Control Strategy (PROCEDURE), Standard Control Strategy (BEHAVIORAL).
Who is sponsoring clinical trial NCT00100386?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00100386's enrollment target sits among peer trials
30,000 8th of 2000 higher than 1,992 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00684580 · 30,000 participants
Protocol For Collecting Data On Patients With Childhood Cancer
- NCT03053193 · 30,000 participants
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
- NCT03689595 · 30,000 participants
Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
- NCT04834869 · 30,000 participants
COVID-19 Vaccines Safety Tracking (CoVaST)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia